Is Measuring Oxidative Stress, Inflammation and Tissue Damage Induced by Intravenous Iron in a Non-Clinical Model Relevant to Clinical Practice?

Key words

ferumoxytol - intravenous iron - oxidative stress

• References

• 1 KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (Suppl. 03) S11-S145
• 2 Stefansson BV, Haraldsson B, Nilsson U. Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 2011; 118: c249-c256
• 3 Toblli JE, Cao G, Oliveri L et al. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung 2011; 61: 399-410
• 4 Balakrishnan VS, Rao M, Kausz AT et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009; 39: 489-496
• 5 Pai AB, Boyd AV, McQuade CR et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350
• 6 Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis – clinical effects, potential treatment, and prevention. Semin Dial 2011; 24: 56-64